ESC 365 - Use of incretin-based therapies.

ESC Premium Access

Use of incretin-based therapies.

Session: How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

Topic: Metabolic Syndrome, Insulin, Insulin Resistance

Speaker: Professor L. Ryden (Stockholm, SE)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

37 presentations

1 follower

3 more presentations in this session

Epigenetic signatures and cardiovascular risk in diabetes.

Speaker: Professor F. Cosentino (Stockholm, SE)

Mechanisms of cardiovascular impact of SGLT2 inhibitors.

Speaker: Professor B. Staels (Lille Cedex, FR)

SGLT2 inhibitors and alteration of substrate metabolism.

Speaker: Professor E. Ferrannini (Pisa, IT)

Access the full session

How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

Speakers: Professor L. Ryden, Professor F. Cosentino, Professor B. Staels, Professor E. Ferrannini

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources